Testing dapagliflozin to protect the heart during breast cancer chemo
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 but not older than 65 years old.
- You have been diagnosed with stage I, II, or III breast cancer (cancer has not spread to other parts of the body).
- You are scheduled to receive at least 4 cycles of the chemotherapy drug doxorubicin.
- You have no history of serious heart problems, such as heart failure, angina, or recent heart surgery.
- You are not pregnant or breastfeeding.
- You have not taken an SGLT2 inhibitor medication (like dapagliflozin) in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
This trial tests if telmisartan, a blood pressure medicine, can protect the heart from damage caused by the chemotherapy drug doxorubicin in women with breast cancer.
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
This trial tests whether two different medications (SGLT-2 inhibitor vs. DPP-4 inhibitor) can help prevent heart damage from certain chemotherapy drugs (anthracyclines) in women with breast cancer. It aims to protect your heart while you undergo cancer treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.